AlphAIAlphAI — Financial news for AI agents
yahoo.com$CRMD

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

CorMedix (CRMD) reported Q2 2026 revenue of $101.9M and adjusted EBITDA of $58.7M. The company signed a commercial supply agreement for DefenCath with a large dialysis organization, covering all top U.S. providers. Full-year revenue guidance was reaffirmed at $325M-$345M, while adjusted EBITDA guidance was raised to $125M-$140M. CorMedix anticipates submitting an sNDA for REZZAYO in Q3 2026, with potential FDA action in H1 2027. The company plans to invest in commercial infrastructure for a pote

Original reporting
yahoo.com
Published Aug 20, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 2:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CorMedix (CRMD) Q2 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$CRMDBullishMed
01

Why it matters

Earnings beat and guidance raise provide a catalyst for short-term price movement; supply agreement expands market reach.

02

Market read

Earnings and guidance update are material for investors in the biotech sector.

03

What to watch

Potential delays in FDA sNDA approval could temper upside.

Relevance 8/10Novelty 8/10Timing: post-earnings Q2 2026 release

Background

CorMedix discussed Q2 results, new supply agreement for DefenCath, and upcoming sNDA submission for REZZAYO.

Company-level read

Ticker impact

$CRMDBullishHigh confidence
Context

CorMedix reported Q2 2026 revenue of $101.9M, adjusted EBITDA of $58.7M and raised full-year adjusted EBITDA guidance to $125-140M.

Expected impact

Potential price appreciation on the back of stronger-than-expected earnings and guidance raise.

Evidence & confidence

First disclosure of earnings and guidance for Q2 2026 with material financial improvements.

Market effects

Sector

Strengthens outlook for infectious disease biotech sector.

Regional

Positive for US biotech investors.

Global

Limited to niche biotech market.

Counterpoint

What could challenge this read

Guidance raise may already be priced in; watch for execution risk.

Key entities

  • Company
    CorMedix

    Biotech firm focused on antifungal and dialysis products.

  • Partner
    Mundipharma

    Collaborator on REZZAYO sNDA submission.

Read at source← All news

Related articles

$CRMDMedAI 8/10

CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex

SEC EDGAR 8-K
$CRMDMed

CorMedix reports $355M cash, reaffirms 2026 revenue guidance

CorMedix (CRMD) reported $355M in cash as of September 30 and reaffirmed its 2026 revenue guidance of $325M-$345M. The CMS set a Q1 2027 Add-on payment for DefenCath at $8.32 per session, within the company's guided range. CorMedix expects the Add-on to decline in Q2 2027 but increase in Q3 and Q4, with the average rate exceeding 2x the current rate. The company plans to discuss financial results on November 12, 2026.

investing.com
$CRMDMed

A federal rule sets an $8.32 add-on payment per DefenCath dialysis session in Q1 2027.

CorMedix Therapeutics (CRMD) reported $355M in cash reserves as of Q3 2026 and reaffirmed its 2026 revenue guidance of $325M-$345M. CMS set an $8.32 Add-on payment per DefenCath dialysis session for Q1 2027, within CorMedix's guided range. The company expects the Add-on to decline in Q2 2027 but increase in later quarters, with an average rate exceeding 2x the current $2.37. CorMedix will discuss its Q3 financial results on November 12, 2026.

stocktitan.net
$CRMDMedAI 8/10

CorMedix Gains FDA Priority Review For REZZAYO's Potential New Indication

CorMedix (CRMD) and Mundipharma's REZZAYO (rezafungin) received FDA Priority Review for preventing invasive fungal diseases. The sNDA is based on the Phase 3 ReSPECT study, with a target action date in Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis. If approved, CorMedix plans to start promotions in H2 2027. CRMD stock is up 0.55% in pre-market trading.

rttnews.com
$CRMDMedAI 8/10

CorMedix Wins Priority Review For REZZAYO SNDA In Fungal Disease Prevention

CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO (rezafungin) to prevent fungal diseases, granting Priority Review. The application, submitted by partner Mundipharma, is based on a Phase 3 trial. The FDA set a target action date for Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis in certain patients. The stock was up 0.55% in pre-market trading.

rttnews.com